| Uceal melanomas arise independent of oncogenic BRAF and NRAS mutations. | skin, |
| Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas. | skin, |
| Mutations of BRAF or KRAS oncogenes are early events in the serrated polyp neoplasia pathway. CpG island methylation plays a role in serrated polyp progression to colorectal carcinoma. | colorectal, |
| Evidence for BRAF mutation and variable levels of microsatellite instability in a syndrome of familial colorectal cancer. | colorectal, |
| Mutations in the BRAF protooncogene (V599E)may be an alternative pathway of tumorigenesis of familial colorectal cancer. | colorectal, |
| Preponderance of the oncogenic V599E and V599K mutations in B-raf kinase domain is enhanced in melanoma cutaneous/subcutaneous metastases. | skin, |
| The results showed that conjunctival nevi, similar to skin nevi, have a high frequency of oncogenic BRAF mutations. | skin, |
| These data suggest that MITF is an anti-proliferation factor that is down-regulated by B-RAF signaling and that this is a crucial event for the progression of melanomas that harbor oncogenic B-RAF. | skin, |
| As the BRAF oncogene is frequently found to be mutated in human cutaneous melanomas, it may constitute a risk factor for melanoma formation within CMN and DMN. | skin, |
| Preponderance of the oncogenic V599E and V599K mutations in the B-raf kinase domain is enhanced in melanoma lymph node metastases. | skin, |
| Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)). | thyroid, |
| The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane. | thyroid, |
| The oncogenic B-raf V599E mutation occurs more frequently in melanomas at sun-protected body sites. | skin, |
| data provide evidence that oncogenic properties of BRAF contribute to the tumorigenesis of intraductal papillary mucinous neoplasm/carcinoma (IPMN/IPMC), but at a lower frequency than KRAS | neoplasm, |
| Targeting BRAF in thyroid cancer. | thyroid, |
| Oncogenic BRaf (V600E) induces benign lung adenomas that progress to malignant lung cancer in cooperation with silencing of either Trp53 or Cdk2n2a in mouse models | lung, |
| Effect of BRAFV600E mutation on transcription and post-transcriptional regulation in a papillary thyroid carcinoma model. | thyroid, |
| The aim of this study was to identify the effect that BRAF oncogene has on post-transcriptional regulation in papillary thyroid carcinoma by using microRNA analysis. | thyroid, |
| Confirmation of a BRAF mutation-associated gene expression signature in melanoma. | skin, |
| T1790A BRAF mutation (L597Q) in childhood acute lymphoblastic leukemia is a functional oncogene | leukemia, |